A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive BHV-4157 in Obsessive Compulsive Disorder
Phase of Trial: Phase II/III
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Troriluzole (Primary)
- Indications Obsessive-compulsive disorders
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical
- 13 Nov 2019 Planned End Date changed from 18 Nov 2020 to 30 Dec 2020.
- 13 Nov 2019 Planned primary completion date changed from 18 Nov 2019 to 30 Dec 2019.
- 07 May 2019 According to a Biohaven Pharmaceutical media release, this study is expected to complete enrollment by end of 2019.